Magenta Therapeutics (MGTA) stock price, revenue, and financials
Magenta Therapeutics market cap is $320.3 m.
$7.01
$320.3 M
MGTA Mkt cap, 18-Nov-2020Magenta Therapeutics Net income (Q3, 2020)-17.7 M
Magenta Therapeutics EBIT (Q3, 2020)-18.4 M
Magenta Therapeutics Cash, 30-Sept-2020141.7 M
Magenta Therapeutics Income Statement
Annual
Quarterly
| USD | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 |
|---|---|---|---|---|---|---|---|---|
R&D expense | 9.7m | 11.4m | 10.5m | 13.4m | 16.5m | 14.0m | 12.6m | 11.8m |
General and administrative expense | 4.3m | 5.3m | 5.8m | 5.9m | 6.1m | 7.3m | 7.4m | 6.6m |
Operating expense total | 14.0m | 16.7m | 16.4m | 19.3m | 22.6m | 21.2m | 20.0m | 18.4m |
EBIT | (14.0m) | (16.7m) | (16.3m) | (19.3m) | (22.6m) | (21.2m) | (20.0m) | (18.4m) |
Interest income | 365.0k | 687.0k | 1.5m | 1.6m | 1.7m | 1.2m | 933.0k | 703.0k |
Income tax expense | ||||||||
Net Income | (13.7m) | (16.0m) | (14.8m) | (17.7m) | (21.0m) | (20.0m) | (19.1m) | (17.7m) |
Magenta Therapeutics Balance Sheet
Annual
| USD | FY, 2018 | FY, 2019 |
|---|---|---|
Cash | 58.3m | 65.1m |
Prepaid Expenses | 2.8m | 4.1m |
Current Assets | 145.3m | 149.8m |
PP&E | 10.2m | 9.9m |
Total Assets | 157.3m | 161.5m |
Accounts Payable | 3.5m | 2.8m |
Current Liabilities | 10.4m | 14.1m |
Non-Current Liabilities | 1.2m | |
Total Liabilities | 11.7m | 20.3m |
Common Stock | 33.0k | 39.0k |
Preferred Stock | ||
Additional Paid-in Capital | 248.3m | 320.6m |
Retained Earnings | (102.7m) | (179.5m) |
Total Equity | 145.6m | 141.2m |
Financial Leverage | 1.1 x | 1.1 x |
Quarterly
| USD | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 |
|---|---|---|---|---|---|---|---|---|
Cash | 173.4m | 159.7m | 31.2m | 33.1m | 85.5m | 74.9m | 136.3m | 141.7m |
Prepaid Expenses | 2.3m | 3.0m | 7.8m | 10.7m | 4.7m | 2.7m | 3.4m | 2.5m |
Current Assets | 175.9m | 162.9m | 135.1m | 183.0m | 165.2m | 133.1m | 179.9m | 164.3m |
PP&E | 2.9m | 8.1m | 10.6m | 10.6m | 10.2m | 9.5m | 9.1m | 8.6m |
Total Assets | 180.6m | 172.8m | 147.7m | 195.4m | 177.2m | 144.4m | 190.7m | 174.6m |
Accounts Payable | 1.5m | 4.9m | 3.0m | 2.3m | 2.0m | 3.9m | 2.7m | 2.4m |
Current Liabilities | 7.6m | 11.9m | 7.9m | 9.9m | 9.6m | 12.7m | 10.4m | 9.9m |
Non-Current Liabilities | 796.0k | 1.1m | ||||||
Total Liabilities | 8.4m | 13.0m | 13.7m | 15.9m | 15.7m | 19.0m | 16.8m | 16.1m |
Common Stock | 33.0k | 33.0k | 34.0k | 39.0k | 39.0k | 39.0k | 48.0k | 48.0k |
Additional Paid-in Capital | 242.2m | 245.8m | 251.5m | 314.6m | 317.7m | 324.5m | 392.3m | 394.7m |
Retained Earnings | (70.0m) | (86.0m) | (117.6m) | (135.3m) | (156.3m) | (199.5m) | (218.6m) | (236.3m) |
Total Equity | 172.2m | 159.8m | 134.0m | 179.6m | 161.5m | 125.4m | 173.9m | 158.6m |
Financial Leverage | 1 x | 1.1 x | 1.1 x | 1.1 x | 1.1 x | 1.2 x | 1.1 x | 1.1 x |
Magenta Therapeutics Cash Flow
Annual
Quarterly
| USD | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 |
|---|---|---|---|---|---|---|---|---|
Net Income | (24.8m) | (40.8m) | (14.8m) | (32.5m) | (53.5m) | (20.0m) | (39.1m) | (56.8m) |
Depreciation and Amortization | 307.0k | 516.0k | 423.0k | 875.0k | 1.4m | 493.0k | 988.0k | 1.5m |
Accounts Payable | 995.0k | 2.1m | (658.0k) | (430.0k) | (629.0k) | 1.1m | (238.0k) | (423.0k) |
Cash From Operating Activities | (18.7m) | (29.3m) | (14.9m) | (30.0m) | (41.5m) | (16.7m) | (35.9m) | (50.3m) |
Purchases of PP&E | (846.0k) | (3.3m) | (1.3m) | (2.4m) | (2.9m) | (131.0k) | (167.0k) | (187.0k) |
Cash From Investing Activities | (2.6m) | (5.1m) | (12.7m) | (56.6m) | 7.3m | 25.4m | 40.4m | 60.3m |
Cash From Financing Activities | 143.4m | 142.6m | 563.0k | 61.3m | 61.4m | 1.1m | 66.7m | 66.6m |
Net Change in Cash | 122.0m | 108.3m | (27.1m) | (25.2m) | 27.2m | 9.9m | 71.2m | 76.6m |
Magenta Therapeutics Ratios
| USD | Q2, 2018 |
|---|---|
Financial Leverage | 1 x |
